TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market

Executive Summary

• TempraMed Technologies Ltd. entered into a definitive exclusive distribution agreement with Dolfin Saglik Ürünleri to sell its VIVI temperature‑controlled medication products throughout Turkey.
• The partnership gives TempraMed access to Turkey’s large diabetes market (≈10 million patients), accelerating its strategic expansion across Europe and beyond.
• The agreement supports TempraMed’s shift from direct‑to‑consumer sales toward retail pharmacy networks, regional distributors, insurers, and institutional healthcare partners.

Key Details

• Parties: TempraMed Technologies Ltd. (CSE: VIVI) and Dolfin Saglik Ürünleri (“Dolfin Saglik”), a leading Turkish medical device distributor founded in 2002.
• Scope: Exclusive right for Dolgin Saglik to market and sell the entire VIVI product line (e.g., VIVI Cap, VIVI Epi) across Turkey.
• Market Opportunity: Turkey has one of the highest diabetes prevalences in Europe; ~10 million people live with diabetes, >1 million use insulin, plus a growing GLP‑1 user base.
• Product Benefits: VIVI devices provide maintenance‑free, smart insulation that protects temperature‑sensitive injectables (insulin, EpiPens, biologics, fertility meds, GLP‑1 therapies) without refrigeration.
• Strategic Fit: Aligns with TempraMed’s defined expansion strategy to transition from online B2C channels to retail pharmacy networks, regional distributors, insurers, and institutional partners.
• CEO Quote (Ron Nagar): Highlights Dolfin’s 20‑year track record, the partnership’s role in accelerating market penetration, and plans for product line expansion, new verticals, and B2C leverage over the next 12 months.
• Dolfin Executive Quote (Tolga ORUÇOGLU): Emphasizes VIVI’s uniqueness in Turkey, its value to insulin‑dependent patients, and commitment to a long‑term partnership.
• Patents: TempraMed holds >8 global patents covering its temperature‑control technology.
• Forward‑Looking Statements: Include expectations for market demand, expansion timeline, and potential risks (adoption speed, regulatory hurdles, macroeconomic factors).

Notable Quotes

“This agreement accelerates our expansion into a large and fast‑growing diabetes market… over the next 12 months we plan to continue expanding our product offering globally, adding new products and verticals, and leveraging our direct‑to‑consumer business to drive new institutional and B2B partnership.” – Ron Nagar, CEO, TempraMed

“VIVI is unlike anything currently available in our market… we look forward to a long‑term partnership with TempraMed and to introducing its products to the Turkish healthcare ecosystem.” – Tolga ORUÇOGLU, General Manager, Dolfin Saglik